Hakutulokset - Ivana Gojo

Tarkenna hakua
  1. 1
    Immune escape and immunotherapy of acute myeloid leukemia

    Immune escape and immunotherapy of acute myeloid leukemia Tekijä Luca Vago, Ivana Gojo

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Myeloid cell factor–1 is a critical survival factor for multiple myeloma

    Myeloid cell factor–1 is a critical survival factor for multiple myeloma Tekijä Bin Zhang, Ivana Gojo, Robert G. Fenton

    Julkaistu 2002
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia

    Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia Tekijä Hanna A. Knaus, Christopher G. Kanakry, Leo Luznik, Ivana Gojo

    Julkaistu 2017
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias

    Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias Tekijä Lisa A. Tobin, Caroline Robert, Aaron P. Rapoport, Ivana Gojo, Maria R. Baer, Alan E. Tomkinson, Feyruz V. Rassool

    Julkaistu 2012
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study

    Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study Tekijä Borislav A. Alexiev, Wenle Wang, Yi Ning, Saranya Chumsri, Ivana Gojo, William H. Rodgers, Sanford A. Stass, Xianfeng Zhao

    Julkaistu 2007
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin

    Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin Tekijä Carine Robert, Pratik Nagaria, Nisha R. Pawar, Adeoluwa Adewuyi, Ivana Gojo, David J. Meyers, Philip A. Cole, Feyruz V. Rassool

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fluda... Tekijä Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low

    Julkaistu 2007
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome Tekijä Ivana Gojo, Alexander E. Perl, Selina M. Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide

    Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclo... Tekijä Shannon R. McCurdy, Brian Iglehart, Denise Batista, Christopher D. Gocke, Yi Ning, Hanna A. Knaus, Annette M. Jackson, Mary S. Leffell, Leo Luznik, Ivana Gojo

    Julkaistu 2016
    Hae kokoteksti
    Carta
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias

    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias Tekijä Ken Shiozawa, Takeo Nakanishi, Ming Tan, Hong-Bin Fang, Wen-chyi Wang, Martin J. Edelman, David P. Carlton, Ivana Gojo, Edward A. Sausville, Douglas D. Ross

    Julkaistu 2009
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome Tekijä Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski, Allen S. Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph Eid, Gregory M. Lubiniecki, Jean–Pierre J. Issa

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy Tekijä Hanna A. Knaus, Sofia Berglund, Hubert Hackl, Amanda L. Blackford, Joshua F. Zeidner, Raul Montiel‐Esparza, Rupkatha Mukhopadhyay, Katrina Vanura, Bruce R. Blazar, Judith E. Karp, Leo Luznik, Ivana Gojo

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid... Tekijä Ivana Gojo, Ming Tan, Hong‐Bin Fang, Mariola Sadowska, Rena G. Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rahul Srivastava, Igor Espinoza‐Delgado, Douglas D. Ross

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide Tekijä Laura Schoch, Kenneth R. Cooke, Nina D. Wagner‐Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark J. Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia

    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia Tekijä Steven D. Gore, Ivana Gojo, Mikkael A. Sekeres, Lawrence E. Morris, Marcel P. Devetten, Katarzyna Jamieson, Robert L. Redner, R.J. Arceci, Ibitayo Owoeye, Tianna Dauses, Esther Schachter-Tokarz, Robert E. Gallagher

    Julkaistu 2010
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) Tekijä Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian, Amy O. Johnson‐Levonas, Craig Fancourt, Raymond W. Lam, Mary Jones, Clayton D. Knox, Shelonitda Rose, Payal Patel, Raoul Tibes

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing

    The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing Tekijä W. Brian Dalton, Eric Helmenstine, Lisa Pieterse, Bing Li, Christopher D. Gocke, Joshua Donaldson, Zhijian Xiao, Lukasz P. Gondek, Gabriel Ghiaur, Ivana Gojo, B. Douglas Smith, Mark J. Levis, Amy E. DeZern

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias Tekijä Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms Tekijä Joshua F. Zeidner, J. E. Karp, Amanda L. Blackford, B. D. Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Judith M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo Tekijä Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Andrew McNally, Ivana Gojo, Judith E. Karp, Ruben A. Mesa, Lisa Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: